During the past decade, NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 15 clinical trials were completed, i.e. on average, 125% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 8 clinical trials were completed. i.e. 160% of trials that started reached the finish line.

Out of the total clinical trials conducted in "NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik" #1 sponsor was "Pfizer" with 9 trials, followed by "Amgen" with 3 trials sponsored, "Eli Lilly and Company" with 2 trials sponsored, "Astellas Pharma Inc" with 1 trials sponsored and "Bristol-Myers Squibb" with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik" #1 collaborator was "Eli Lilly and Company" with 1 trials as a collaborator, "Incyte Corporation" with 1 trials as a collaborator and "Shire" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik" are "Rheumatoid Arthritis" (6 trials), "Psoriatic Arthritis" (3 trials), "Cardiovascular Disease" (2 trials), "Ankylosing Spondyloarthritis" (1 trials) and "Arthritis, Psoriatic" (1 trials). Many other conditions were trialed in "NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik" in a lesser frequency.

Most popular intervention types in "NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik" are "Drug" (19 trials), "Other" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Methotrexate" (3 trials), "Adalimumab" (2 trials), "bococizumab (PF-04950615)" (2 trials) and "Apremilast 20 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik" are 19 trials for "All" genders.

Currently, there are NaN active trials in "NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in NZOZ Osteo-Medic s.c. Artur Racewicz, Jerzy Supronik, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".